prazosin has been researched along with Cardiomegaly in 58 studies
Prazosin: A selective adrenergic alpha-1 antagonist used in the treatment of HEART FAILURE; HYPERTENSION; PHEOCHROMOCYTOMA; RAYNAUD DISEASE; PROSTATIC HYPERTROPHY; and URINARY RETENTION.
prazosin : A member of the class of piperazines that is piperazine substituted by a furan-2-ylcarbonyl group and a 4-amino-6,7-dimethoxyquinazolin-2-yl group at positions 1 and 4 respectively.
Cardiomegaly: Enlargement of the HEART, usually indicated by a cardiothoracic ratio above 0.50. Heart enlargement may involve the right, the left, or both HEART VENTRICLES or HEART ATRIA. Cardiomegaly is a nonspecific symptom seen in patients with chronic systolic heart failure (HEART FAILURE) or several forms of CARDIOMYOPATHIES.
Excerpt | Relevance | Reference |
---|---|---|
"Sixteen patients with mild or moderate essential hypertension received 1 to 8 mg/day of doxazosin (mean daily dose, 2." | 9.07 | Doxazosin in the treatment of mild or moderate essential hypertension: an echocardiographic study. ( Corral, JL; López, NC; Pecorelli, A; Rincón, LA; Terán, VD, 1991) |
"A single daily dose of doxazosin taken during a 12-week period produced a significant reduction in blood pressure and left ventricular mass index in patients with mild or moderate hypertension." | 9.07 | Echocardiographic assessment of doxazosin on left ventricular mass in patients with essential hypertension. ( Fonseca, R; López, B; Lugo de Franco, V; Medina, O; Monsalve, P; Ostojich, K; Pérez Acuña, F; Torres, N; Vera, O, 1991) |
"The stimulus for carbon monoxide-induced cardiac hypertrophy was investigated." | 7.68 | Carbon monoxide-induced cardiac hypertrophy is not reduced by alpha- or beta-blockade in the rat. ( Formolo, JM; Penney, DG, 1993) |
"There is evidence that cardiac hypertrophy in spontaneously hypertensive rats (SHR) occurs before the development of hypertension." | 5.28 | Enalapril reduces the enhanced 1,2-diacylglycerol content and RNA synthesis in spontaneously hypertensive rat hearts before established hypertension. ( Asano, H; Hashimoto, H; Ishikawa, K; Ito, T; Kondo, J; Okumura, K; Yoshino, M, 1992) |
"Although treatment of hypertension per se is important, blood pressure alone may not explain the course of the hypertrophic process." | 5.28 | Regression of left ventricular hypertrophy in hypertension. Effects of prazosin therapy. ( Corbett, J; Gonzalez, D; Kaplan, NM; Kulkarni, P; Ram, CV; Sunderajan, P; Taylor, A; Zachariah, NY, 1989) |
"Sixteen patients with mild or moderate essential hypertension received 1 to 8 mg/day of doxazosin (mean daily dose, 2." | 5.07 | Doxazosin in the treatment of mild or moderate essential hypertension: an echocardiographic study. ( Corral, JL; López, NC; Pecorelli, A; Rincón, LA; Terán, VD, 1991) |
"A single daily dose of doxazosin taken during a 12-week period produced a significant reduction in blood pressure and left ventricular mass index in patients with mild or moderate hypertension." | 5.07 | Echocardiographic assessment of doxazosin on left ventricular mass in patients with essential hypertension. ( Fonseca, R; López, B; Lugo de Franco, V; Medina, O; Monsalve, P; Ostojich, K; Pérez Acuña, F; Torres, N; Vera, O, 1991) |
" Since left ventricular hypertrophy may be an important determinant of outcome in hypertension, the long-term effects of arterial vasodilation with hydralazine on left ventricular mass and function were compared with those of an alternative third-line drug, the alpha1 blocker prazosin, in patients still hypertensive despite combined diuretic and beta blocker therapy." | 5.06 | Vasodilators and regression of left ventricular hypertrophy. Hydralazine versus prazosin in hypertensive humans. ( Farkas, RM; Leenen, FH; Marquez-Julio, A; Reeves, RA; Smith, DL, 1987) |
" In this article, doxazosin is reviewed for its efficacy in the treatment of severe essential hypertension and specific complications or conditions of mild or moderate essential hypertension, namely, left ventricular hypertrophy, hyperlipidemia, noninsulin-dependent diabetes mellitus, renal insufficiency, pheochromocytoma, chronic obstructive pulmonary disease, peripheral vascular disease, and smoking." | 4.78 | Efficacy of doxazosin in specific hypertensive patient groups. ( Taylor, SH, 1991) |
" Atenolol neither modified HR nor BP variability in rats with hyperthyroidism." | 3.70 | Autonomic contribution to the blood pressure and heart rate variability changes in early experimental hyperthyroidism. ( Elghozi, JL; Laude, D; Ponchon, P; Safa-Tisseront, V, 1998) |
"The stimulus for carbon monoxide-induced cardiac hypertrophy was investigated." | 3.68 | Carbon monoxide-induced cardiac hypertrophy is not reduced by alpha- or beta-blockade in the rat. ( Formolo, JM; Penney, DG, 1993) |
"The development of cardiac hypertrophy was examined in rats given ethanol in a nutritionally adequate, liquid diet mixture, by intubation, in severely intoxicating doses at 8-h intervals for up to 96 h, alone or in combination with prazosin." | 3.67 | Lack of cardiac alpha 1-adrenoceptor involvement in ethanol-induced cardiac hypertrophy. ( Adams, MA; Hirst, M, 1989) |
" On this basis, functional and therapeutical regimen of regression of cardiac hypertrophy (prazosin, clonidine, nifedipine) are analyzed in concentric as well as in excentric hypertrophy in patients with arterial hypertension." | 3.67 | [Progression and regression of heart hypertrophy in arterial hypertension: pathophysiology and clinical aspects]. ( Strauer, BE, 1985) |
"Ventricular arrhythmia was a significant independent predictor in V-HeFT II but not in V-HeFT I." | 2.67 | Ejection fraction, peak exercise oxygen consumption, cardiothoracic ratio, ventricular arrhythmias, and plasma norepinephrine as determinants of prognosis in heart failure. The V-HeFT VA Cooperative Studies Group. ( Cohn, JN; Fletcher, R; Johnson, GR; Loeb, H; Rector, T; Shabetai, R; Smith, R; Tristani, F, 1993) |
"Adenosine has been shown to exert direct antihypertrophic effects on the heart, and plasma adenosine levels have been shown to be elevated in patients with heart failure." | 1.36 | Compensatory upregulation of the adenosine system following phenylephrine-induced hypertrophy in cultured rat ventricular myocytes. ( Cook, MA; Freeman, DJ; Gan, XT; Karmazyn, M; Pang, T, 2010) |
"Although norepinephrine induces cardiac hypertrophy by activating protein kinase A and C through beta- and alpha 1-adrenoceptors, respectively, protein kinase A has been reported to inhibit cell growth in many other cell types." | 1.30 | Norepinephrine induces the raf-1 kinase/mitogen-activated protein kinase cascade through both alpha 1- and beta-adrenoceptors. ( Aikawa, R; Hiroi, Y; Komuro, I; Kudoh, S; Mizuno, T; Shiojima, I; Takano, H; Yamazaki, T; Yazaki, Y; Zou, Y, 1997) |
"Regression of cardiac hypertrophy occurred after treatment of aortic banded rats with a high dose of enalapril, bunazosin or propranolol, and was accompanied by a reduction in systolic blood pressure." | 1.29 | Modulation of adrenergic receptors during regression of cardiac hypertrophy. ( Hata, T; Makino, N; Matsui, H; Nakanishi, H; Yanaga, T; Yano, K, 1994) |
" Therefore, after 4 weeks of washout with placebo (phase 1), doxazosin (dosage range from 1 to 16 mg, plus hydrochlorothiazide when necessary) was given to 11 essential hypertensive patients (6 M, 5 F, age range 34-63 years) for 8 weeks (phase 2) in order to achieve diastolic blood pressure values less than 90 mmHg; this dosage was then maintained for a further 20 weeks up to the end of the study (phase 3)." | 1.28 | Reduction of left ventricular hypertrophy after longterm antihypertensive treatment with doxazosin. ( Agabiti-Rosei, E; Beschi, M; Calebich, S; Castellano, M; Muiesan, G; Muiesan, ML; Rizzoni, D; Zulli, R, 1992) |
"There is evidence that cardiac hypertrophy in spontaneously hypertensive rats (SHR) occurs before the development of hypertension." | 1.28 | Enalapril reduces the enhanced 1,2-diacylglycerol content and RNA synthesis in spontaneously hypertensive rat hearts before established hypertension. ( Asano, H; Hashimoto, H; Ishikawa, K; Ito, T; Kondo, J; Okumura, K; Yoshino, M, 1992) |
"Na+ influx may also be involved in cardiac hypertrophy induced by catecholamine." | 1.28 | The role of Na+/H+ exchange in norepinephrine-induced protein synthesis in neonatal cultured rat cardiomyocytes. ( Hori, M; Iwai, K; Iwakura, K; Kagiya, T; Kamada, T; Kitabatake, A; Nakatsubo, N; Sato, H, 1990) |
"Although treatment of hypertension per se is important, blood pressure alone may not explain the course of the hypertrophic process." | 1.28 | Regression of left ventricular hypertrophy in hypertension. Effects of prazosin therapy. ( Corbett, J; Gonzalez, D; Kaplan, NM; Kulkarni, P; Ram, CV; Sunderajan, P; Taylor, A; Zachariah, NY, 1989) |
"Thus, the rapid development of cardiac hypertrophy in the norepinephrine model seems to be directly mediated by stimulation of myocardial alpha- and beta-adrenoceptors rather than by hemodynamic changes." | 1.28 | Significance of myocardial alpha- and beta-adrenoceptors in catecholamine-induced cardiac hypertrophy. ( Zierhut, W; Zimmer, HG, 1989) |
"In hypertensive cardiac hypertrophy, inotropic responsiveness of alpha and beta adrenergic stimuli is reduced." | 1.27 | Excitation-contraction coupling in hypertrophied myocardium. ( Fouad, FM; Hanna, MK; Khairallah, PA; Upsher, ME; Yoshida, K, 1985) |
"Even though cardiac hypertrophy is viewed as a beneficial compensatory process that normalizes wall stress, the increased muscle mass carries with it the need of increased blood supply." | 1.27 | Effects of vasodilators on the coronary circulation in congestive heart failure. ( Burkart, F; Kiowski, W, 1988) |
"Renal hypertrophy was also decreased significantly by cicletanine at a dose of 100 mg/kg." | 1.27 | Comparison of cicletanine with other antihypertensive drugs in SHR-SP models. ( Braquet, P; Clostre, F; Le Hegarat, M; Malherbe, E, 1988) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 30 (51.72) | 18.7374 |
1990's | 22 (37.93) | 18.2507 |
2000's | 4 (6.90) | 29.6817 |
2010's | 2 (3.45) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Pang, T | 1 |
Gan, XT | 1 |
Freeman, DJ | 1 |
Cook, MA | 1 |
Karmazyn, M | 1 |
Wang, GJ | 1 |
Yao, YS | 1 |
Wang, HX | 1 |
Barron, AJ | 1 |
Finn, SG | 1 |
Fuller, SJ | 1 |
Isabelle, M | 1 |
Monteil, C | 1 |
Moritz, F | 1 |
Dautreaux, B | 1 |
Henry, JP | 1 |
Richard, V | 1 |
Mulder, P | 1 |
Thuillez, C | 1 |
Lampa, E | 1 |
Rossi, F | 2 |
Aliperta, A | 1 |
Giordano, L | 1 |
Perna, D | 1 |
Catena, E | 1 |
Marmo, E | 1 |
Nelson, GI | 2 |
Hunyor, SN | 2 |
Donnelly, GL | 2 |
Simpson, P | 2 |
Ruskoaho, H | 1 |
Khairallah, PA | 3 |
Hanna, MK | 3 |
Tarazi, RC | 1 |
Upsher, ME | 2 |
Yoshida, K | 3 |
Bolte, HD | 1 |
Bussmann, WD | 1 |
Antani, JA | 1 |
Harrison, DC | 1 |
Feldman, RC | 1 |
Ball, RM | 1 |
Giudicelli, JF | 1 |
Freslon, JL | 1 |
Richer, C | 1 |
Matsui, H | 1 |
Makino, N | 1 |
Yano, K | 1 |
Nakanishi, H | 1 |
Hata, T | 1 |
Yanaga, T | 1 |
Fregly, MJ | 1 |
Sun, Z | 1 |
Tümer, N | 1 |
Cade, JR | 1 |
Hegland, D | 1 |
Yürekli, M | 1 |
Takahashi, N | 1 |
Calderone, A | 1 |
Izzo, NJ | 1 |
Mäki, TM | 1 |
Marsh, JD | 1 |
Colucci, WS | 2 |
Penney, DG | 1 |
Formolo, JM | 1 |
Cohn, JN | 1 |
Johnson, GR | 1 |
Shabetai, R | 1 |
Loeb, H | 1 |
Tristani, F | 1 |
Rector, T | 1 |
Smith, R | 1 |
Fletcher, R | 1 |
Rokosh, DG | 1 |
Stewart, AF | 1 |
Chang, KC | 1 |
Bailey, BA | 1 |
Karliner, JS | 1 |
Camacho, SA | 1 |
Long, CS | 1 |
Simpson, PC | 2 |
Yamazaki, T | 1 |
Komuro, I | 1 |
Zou, Y | 1 |
Kudoh, S | 1 |
Shiojima, I | 1 |
Hiroi, Y | 1 |
Mizuno, T | 1 |
Aikawa, R | 1 |
Takano, H | 1 |
Yazaki, Y | 1 |
Schnabel, P | 1 |
Nohr, T | 1 |
Nickenig, G | 1 |
Paul, M | 1 |
Böhm, M | 1 |
Gaughan, JP | 1 |
Hefner, CA | 1 |
Houser, SR | 1 |
Grupp, IL | 1 |
Lorenz, JN | 1 |
Walsh, RA | 1 |
Boivin, GP | 1 |
Rindt, H | 1 |
Safa-Tisseront, V | 1 |
Ponchon, P | 1 |
Laude, D | 1 |
Elghozi, JL | 1 |
Hwang, B | 1 |
Qu, TY | 1 |
Hu, CT | 1 |
Chen, HI | 1 |
Xiao, L | 1 |
Pimental, DR | 1 |
Amin, JK | 1 |
Singh, K | 1 |
Sawyer, DB | 1 |
Mier, K | 1 |
Kemken, D | 1 |
Katus, HA | 1 |
Richardt, G | 1 |
Kurz, T | 1 |
Lloyd, EA | 1 |
Agabiti-Rosei, E | 1 |
Muiesan, ML | 1 |
Rizzoni, D | 1 |
Zulli, R | 1 |
Calebich, S | 1 |
Beschi, M | 1 |
Castellano, M | 1 |
Muiesan, G | 1 |
Leren, P | 1 |
Okumura, K | 1 |
Kondo, J | 1 |
Yoshino, M | 1 |
Ishikawa, K | 1 |
Asano, H | 1 |
Hashimoto, H | 2 |
Ito, T | 1 |
Taylor, SH | 1 |
Corral, JL | 1 |
López, NC | 1 |
Pecorelli, A | 1 |
Rincón, LA | 1 |
Terán, VD | 1 |
Monsalve, P | 1 |
Vera, O | 1 |
Pérez Acuña, F | 1 |
Medina, O | 1 |
Ostojich, K | 1 |
López, B | 1 |
Torres, N | 1 |
Lugo de Franco, V | 1 |
Fonseca, R | 1 |
Bache, RJ | 1 |
Homans, DC | 1 |
Dai, XZ | 1 |
Yasumoto, K | 1 |
Takata, M | 1 |
Mikawa, M | 1 |
Tomoda, F | 1 |
Sasayama, S | 1 |
Itaya, T | 1 |
Satoh, R | 1 |
Uematsu, T | 1 |
Nakashima, M | 1 |
Hori, M | 1 |
Nakatsubo, N | 1 |
Kagiya, T | 1 |
Iwai, K | 1 |
Sato, H | 1 |
Iwakura, K | 1 |
Kitabatake, A | 1 |
Kamada, T | 1 |
Fouad, FM | 1 |
Sharma, RV | 1 |
Butters, CA | 1 |
Bhalla, RC | 1 |
Motz, W | 1 |
Klepzig, M | 1 |
Strauer, BE | 2 |
Leenen, FH | 2 |
Ram, CV | 1 |
Gonzalez, D | 1 |
Kulkarni, P | 1 |
Sunderajan, P | 1 |
Corbett, J | 1 |
Taylor, A | 1 |
Zachariah, NY | 1 |
Kaplan, NM | 1 |
Adams, MA | 1 |
Hirst, M | 1 |
Zierhut, W | 1 |
Zimmer, HG | 1 |
Bishopric, NH | 1 |
Ordahl, CP | 1 |
Jennings, AA | 1 |
Jee, LD | 1 |
Smith, JA | 1 |
Commerford, PJ | 1 |
Opie, LH | 1 |
Limas, CJ | 1 |
Limas, C | 1 |
Rambausek, M | 1 |
Ritz, E | 1 |
Mall, G | 1 |
Mehls, O | 1 |
Katus, H | 1 |
Smith, DL | 1 |
Farkas, RM | 1 |
Reeves, RA | 1 |
Marquez-Julio, A | 1 |
Kiowski, W | 1 |
Burkart, F | 1 |
Malherbe, E | 2 |
Le Hegarat, M | 2 |
Clostre, F | 2 |
Braquet, P | 2 |
Auguet, M | 1 |
Delaflotte, S | 1 |
Baranes, J | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Anxiety-mediated Impairments in Large Elastic Artery Function and the Autonomic Nervous System[NCT03109795] | Phase 4 | 30 participants (Actual) | Interventional | 2017-04-10 | Terminated (stopped due to Funding ended) | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
5 reviews available for prazosin and Cardiomegaly
Article | Year |
---|---|
[Treatment of heart failure with vasodilators].
Topics: Captopril; Cardiomegaly; Cardiotonic Agents; Coronary Disease; Heart Failure; Heart Function Tests; | 1980 |
[Effect of vasodilator agents in chronic heart failure].
Topics: Cardiomegaly; Clinical Trials as Topic; Heart Failure; Hemodynamics; Humans; Isosorbide Dinitrate; P | 1981 |
The use of vasodilator agents in the treatment of heart failure.
Topics: Cardiac Output; Cardiomegaly; Catheterization; Chronic Disease; Coronary Vessels; Dose-Response Rela | 1979 |
The cardiovascular effects of alpha-receptor blocking agents.
Topics: Adrenergic alpha-Antagonists; Animals; Antihypertensive Agents; Cardiomegaly; Cardiovascular System; | 1992 |
Efficacy of doxazosin in specific hypertensive patient groups.
Topics: Adrenal Gland Neoplasms; Antihypertensive Agents; Cardiomegaly; Diabetes Mellitus, Type 2; Doxazosin | 1991 |
8 trials available for prazosin and Cardiomegaly
Article | Year |
---|---|
Rest and exercise haemodynamic patterns with chronic prazosin or beta-blocker therapy in hypertensive cardiomegaly.
Topics: Adrenergic beta-Antagonists; Aged; Blood Pressure; Cardiomegaly; Clinical Trials as Topic; Female; H | 1980 |
[Effect of vasodilator agents in chronic heart failure].
Topics: Cardiomegaly; Clinical Trials as Topic; Heart Failure; Hemodynamics; Humans; Isosorbide Dinitrate; P | 1981 |
[Prazosin in arterial hypertension with cardiac insufficiency].
Topics: Adult; Aged; Cardiomegaly; Clinical Trials as Topic; Drug Therapy, Combination; Electrocardiography; | 1980 |
Combined pre- and after-load reduction in hypertensive patients with cardiomegaly and normal filling pressure.
Topics: Aged; Cardiomegaly; Hemodynamics; Humans; Hypertension; Middle Aged; Physical Exertion; Prazosin; Pr | 1981 |
Ejection fraction, peak exercise oxygen consumption, cardiothoracic ratio, ventricular arrhythmias, and plasma norepinephrine as determinants of prognosis in heart failure. The V-HeFT VA Cooperative Studies Group.
Topics: Arrhythmias, Cardiac; Cardiomegaly; Drug Therapy, Combination; Enalapril; Heart Failure; Humans; Hyd | 1993 |
Doxazosin in the treatment of mild or moderate essential hypertension: an echocardiographic study.
Topics: Adult; Antihypertensive Agents; Cardiomegaly; Doxazosin; Echocardiography; Female; Humans; Hypertens | 1991 |
Echocardiographic assessment of doxazosin on left ventricular mass in patients with essential hypertension.
Topics: Antihypertensive Agents; Cardiomegaly; Cholesterol; Coronary Disease; Doxazosin; Echocardiography; F | 1991 |
Vasodilators and regression of left ventricular hypertrophy. Hydralazine versus prazosin in hypertensive humans.
Topics: Adult; Cardiomegaly; Female; Humans; Hydralazine; Hypertension; Male; Middle Aged; Prazosin; Vasodil | 1987 |
46 other studies available for prazosin and Cardiomegaly
Article | Year |
---|---|
Compensatory upregulation of the adenosine system following phenylephrine-induced hypertrophy in cultured rat ventricular myocytes.
Topics: Adenosine; Animals; Animals, Newborn; Cardiomegaly; Cells, Cultured; Disease Models, Animal; Heart V | 2010 |
[Comparing effects of U50488H, prazosin and/or propranolol on cardiac hypertrophy induced by NE in rat].
Topics: 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; Adrenergic | 2010 |
Chronic activation of extracellular-signal-regulated protein kinases by phenylephrine is required to elicit a hypertrophic response in cardiac myocytes.
Topics: Adrenergic alpha-Antagonists; Animals; Atrial Natriuretic Factor; Benzamides; Butadienes; Cardiomega | 2003 |
Role of alpha1-adrenoreceptors in cocaine-induced NADPH oxidase expression and cardiac dysfunction.
Topics: Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Animals; Cardiomegaly; Cardiomyopathies; Co | 2005 |
A study on the effects of some drugs on DOCA induced hypertension in the rat.
Topics: Adrenergic alpha-Agonists; Animals; Blood Pressure; Cardiomegaly; Desoxycorticosterone; Diuretics; H | 1980 |
Norepinephrine-stimulated hypertrophy of cultured rat myocardial cells is an alpha 1 adrenergic response.
Topics: Adrenergic alpha-Antagonists; Animals; Cardiomegaly; Isoproterenol; Myocardium; Norepinephrine; Phen | 1983 |
Prevention of cardiac hypertrophy by long-term treatment with isosorbide dinitrate and prazosin but not by minoxidil in spontaneously hypertensive rats.
Topics: Animals; Blood Pressure; Cardiomegaly; Female; Hypertension; Isosorbide Dinitrate; Male; Minoxidil; | 1984 |
Biochemical alterations in cardiac hypertrophy.
Topics: Animals; Cardiomegaly; Dihydroalprenolol; Hypertension; Myocardium; Prazosin; Protein Kinases; Rats; | 1984 |
[Sustained and beneficial hemodynamic effects of prazosin in cardiac insufficiency].
Topics: Blood Pressure; Cardiac Output; Cardiomegaly; Heart Failure; Hemodynamics; Humans; Prazosin; Pulmona | 1980 |
[Antihypertensives and the prevention of development of genetic hypertension in the hypertensive SHR rat].
Topics: Animals; Antihypertensive Agents; Atenolol; Captopril; Cardiomegaly; Dihydralazine; Dose-Response Re | 1980 |
Modulation of adrenergic receptors during regression of cardiac hypertrophy.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Cardiomegaly; Iodocyanopindolol; Male; Norepineph | 1994 |
Effect of chronic treatment with prazosin and L-arginine on the elevation of blood pressure during cold exposure.
Topics: Adrenal Glands; Angiotensin II; Animals; Arginine; Blood Pressure; Cardiomegaly; Cold Temperature; E | 1994 |
Hypertrophic stimuli induce transforming growth factor-beta 1 expression in rat ventricular myocytes.
Topics: Animals; Animals, Newborn; Aorta, Abdominal; Atrial Natriuretic Factor; Cardiomegaly; Cells, Culture | 1994 |
Carbon monoxide-induced cardiac hypertrophy is not reduced by alpha- or beta-blockade in the rat.
Topics: Animals; Atenolol; Blood Pressure; Body Weight; Carbon Monoxide; Cardiomegaly; Heart Rate; Lung; Mal | 1993 |
Alpha1-adrenergic receptor subtype mRNAs are differentially regulated by alpha1-adrenergic and other hypertrophic stimuli in cardiac myocytes in culture and in vivo. Repression of alpha1B and alpha1D but induction of alpha1C.
Topics: Adrenergic alpha-Agonists; Animals; Animals, Newborn; Cardiomegaly; Cells, Cultured; Endothelins; Ge | 1996 |
Norepinephrine induces the raf-1 kinase/mitogen-activated protein kinase cascade through both alpha 1- and beta-adrenoceptors.
Topics: 1-Methyl-3-isobutylxanthine; Adrenergic alpha-1 Receptor Antagonists; Amino Acids; Animals; Animals, | 1997 |
Alpha-adrenergic signal transduction in renin transgenic rats.
Topics: Animals; Animals, Genetically Modified; Cardiomegaly; Cell Membrane; GTP-Binding Proteins; Mice; Myo | 1997 |
Electrophysiological properties of neonatal rat ventricular myocytes with alpha1-adrenergic-induced hypertrophy.
Topics: Action Potentials; Adrenergic alpha-1 Receptor Agonists; Analysis of Variance; Animals; Animals, New | 1998 |
Overexpression of alpha1B-adrenergic receptor induces left ventricular dysfunction in the absence of hypertrophy.
Topics: Adrenergic alpha-1 Receptor Antagonists; Animals; Blood Pressure; Calcium; Cardiomegaly; Cells, Cult | 1998 |
Autonomic contribution to the blood pressure and heart rate variability changes in early experimental hyperthyroidism.
Topics: Animals; Atenolol; Atropine; Autonomic Nervous System; Blood Pressure; Cardiomegaly; Disease Models, | 1998 |
Hemodynamic and neurohumoral changes after abdominal aortic constriction in rats.
Topics: Animals; Aorta, Abdominal; Captopril; Cardiac Output; Cardiomegaly; Catecholamines; Constriction; El | 1999 |
MEK1/2-ERK1/2 mediates alpha1-adrenergic receptor-stimulated hypertrophy in adult rat ventricular myocytes.
Topics: Adrenergic alpha-Agonists; Adrenergic beta-Antagonists; Animals; Cardiomegaly; Cells, Cultured; Enzy | 2001 |
Adrenergic activation of cardiac phospholipase D: role of alpha(1)-adrenoceptor subtypes.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Animals; Cardiomegaly; Clonidine; Dioxane | 2002 |
Reduction of left ventricular hypertrophy after longterm antihypertensive treatment with doxazosin.
Topics: Adrenergic alpha-Antagonists; Adult; Aldosterone; Antihypertensive Agents; Blood Pressure; Cardiomeg | 1992 |
Enalapril reduces the enhanced 1,2-diacylglycerol content and RNA synthesis in spontaneously hypertensive rat hearts before established hypertension.
Topics: Animals; Body Weight; Cardiomegaly; Diglycerides; Enalapril; Heart Ventricles; Hypertension; Lipids; | 1992 |
Adrenergic vasoconstriction limits coronary blood flow during exercise in hypertrophied left ventricle.
Topics: Animals; Cardiomegaly; Coronary Circulation; Dogs; Heart Ventricles; Hemodynamics; Myocardium; Oxyge | 1991 |
Reversal of left ventricular hypertrophy by terazosin in hypertensive patients.
Topics: Adrenergic alpha-Antagonists; Aged; Cardiomegaly; Drug Evaluation; Electrocardiography; Female; Hear | 1990 |
Increases in alpha-but not beta-adrenoceptors in hypertrophied non-infarcted cardiac muscles from rats with chronic myocardial infarction.
Topics: Animals; Body Weight; Cardiomegaly; Coronary Vessels; Dihydroalprenolol; Male; Muscle Proteins; Myoc | 1990 |
The role of Na+/H+ exchange in norepinephrine-induced protein synthesis in neonatal cultured rat cardiomyocytes.
Topics: Amiloride; Analysis of Variance; Animals; Animals, Newborn; Cardiomegaly; Cells, Cultured; Ion Excha | 1990 |
Excitation-contraction coupling in hypertrophied myocardium.
Topics: Age Factors; Angiotensin II; Animals; Blood Pressure; Cardiomegaly; Epinephrine; Heart; Hypertension | 1985 |
Alterations in the plasma membrane properties of the myocardium of spontaneously hypertensive rats.
Topics: Adenosine Triphosphatases; Animals; Cardiomegaly; Cell Membrane; Ion Channels; Male; Myocardium; Nif | 1986 |
Regression of cardiac hypertrophy: experimental and clinical results.
Topics: Animals; Cardiomegaly; Clonidine; Enalapril; Humans; Hypertension; Nifedipine; Prazosin; Rats; Rats, | 1987 |
Left ventricular hypertrophy in hypertensive patients.
Topics: Cardiomegaly; Drug Therapy, Combination; Humans; Hydralazine; Hypertension; Prazosin | 1989 |
Regression of left ventricular hypertrophy in hypertension. Effects of prazosin therapy.
Topics: Blood Pressure; Cardiomegaly; Echocardiography; Female; Heart; Humans; Hypertension; Male; Middle Ag | 1989 |
Lack of cardiac alpha 1-adrenoceptor involvement in ethanol-induced cardiac hypertrophy.
Topics: Adrenal Glands; Animals; Behavior, Animal; Body Weight; Cardiomegaly; Catecholamines; Ethanol; Male; | 1989 |
Significance of myocardial alpha- and beta-adrenoceptors in catecholamine-induced cardiac hypertrophy.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Animals; Cardiomegaly; DNA; Female; Myoca | 1989 |
Induction of the skeletal alpha-actin gene in alpha 1-adrenoceptor-mediated hypertrophy of rat cardiac myocytes.
Topics: Actins; Animals; Cardiomegaly; Cells, Cultured; Dose-Response Relationship, Drug; Isoproterenol; Myo | 1987 |
Acute effect of nifedipine on blood pressure and left ventricular ejection fraction in severely hypertensive outpatients: predictive effects of acute therapy and prolonged efficacy when added to existing therapy.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Blood Pressure; Cardiomegaly; Drug Therapy, Combination; F | 1986 |
Altered intracellular adrenoceptor distribution in myocardium of spontaneously hypertensive rats.
Topics: Adrenergic beta-Agonists; Animals; Cardiomegaly; Cell Membrane; Cytosol; Dihydroalprenolol; Hyperten | 1987 |
Myocardial hypertrophy in rats with renal insufficiency.
Topics: Adenosine Triphosphatases; Animals; Blood Pressure; Blood Transfusion; Calcium; Cardiomegaly; Hydral | 1985 |
[Progression and regression of heart hypertrophy in arterial hypertension: pathophysiology and clinical aspects].
Topics: Blood Pressure; Cardiac Volume; Cardiomegaly; Cardiomyopathy, Hypertrophic; Clonidine; Coronary Circ | 1985 |
Effects of vasodilators on the coronary circulation in congestive heart failure.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Calcium Channel Blockers; Cardiomegaly; Cilazapri | 1988 |
Comparison of cicletanine with other antihypertensive drugs in SHR-SP models.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Body Weight; Captopril; Cardiomegaly; Diuresis; Di | 1988 |
Antihypertensive profile of cicletanine, a furopyridine derivative: comparison with captopril, indapamide and prazosin.
Topics: Animals; Antihypertensive Agents; Aorta; Blood Pressure; Captopril; Cardiomegaly; Diuresis; Diuretic | 1988 |
Stimulation of hypertrophy of cultured neonatal rat heart cells through an alpha 1-adrenergic receptor and induction of beating through an alpha 1- and beta 1-adrenergic receptor interaction. Evidence for independent regulation of growth and beating.
Topics: Animals; Ascorbic Acid; Cardiomegaly; Cell Division; Cells, Cultured; Cycloheximide; Dopamine; Heart | 1985 |
Alterations of myocardial alpha 1-adrenergic receptors in hypertensive cardiac hypertrophy in the rat.
Topics: Aging; Animals; Blood Pressure; Cardiomegaly; Hypertension; Hypertension, Renal; Male; Myocardium; O | 1986 |